×
Third quarter 2026 revenue rose 7% year over year to $91.9 million , led by a 13% increase in lymphedema products to $81.8 million. Airway clearance (AffloVest) revenue fell 25% to $10.0 million amid a durable medical equipment (DME) inventory transition tied to a new product launch.
Third-quarter 2026 revenue rose 3% to $142.4 million but missed the roughly $149.5 million consensus estimate. Adjusted earnings per share (EPS) came in at $0.17, topping analyst expectations and up 13% from $0.15 a year earlier.
Worldwide revenue reached $55.7 million in the third quarter of 2026, up 14.5% year over year from $48.7 million. Net loss narrowed to $3.6 million , or $0.08 per diluted share , beating the consensus estimate of a $0.13 per share loss.
UFP Technologies, Inc. (UFPT) is scheduled to report its third quarter 2026 results on Tuesday, November 3, 2026, after the market close , with a conference call on November 4 at 8:30 a.m. ET. Consensus estimates tracked by MarketBeat point to earnings per share (EPS) of $2.49 on revenue of roughly $166.89 million for the September 2026 quarter.
Inspire Medical Systems (INSP) reported third-quarter 2025 revenue of $224.5 million, up 10% from $203.2 million in the prior-year period. Adjusted earnings per share (EPS) came in at $0.38, far ahead of the consensus estimate for a loss of $0.19 per share.
SNWV shares climbed roughly 21% over the last 30 days, rising from about $4.82 to near $5.84, as the stock rebounded from multi-year lows reached in early September. The recovery followed a sharp drawdown that took the stock to a 52-week low of $3.92, with shares still trading far below their 52-week high of $36.20.
iTonic Holdings (ITOC) dropped -17.69% during regular market hours, sliding from a $2.60 previous close to $2.14. No verified news or fundamental catalyst found. The decline is consistent with continued selling pressure in a thinly-traded micro-cap that is still unwinding after its October 6 16-for-1 reverse stock split.
AVR shares fell roughly 25% over the last 30 days, declining from about $7.71 to near $5.79, extending a broader multi-month pullback. The stock is down approximately 30% over the last three months after peaking near $9.83 in mid-August.
AVR slid from its $6.31 Oct 30 close to $5.83, down -7.61%, during regular market hours, reversing an earlier premarket gap up. Anteris reported positive 30-day DurAVR EMBARK study data at the TCT 2026 conference early Nov 2, gapping shares higher in premarket; the stock then reversed and sold off through the regular session in a sell-the-news, profit-taking move with no new negative catalyst.
Pediatric label expansion is the central catalyst. Nuwellis completed an FDA (U.S. Food and Drug Administration) pre-submission meeting and plans to file a 510(k) application by the end of 2026 to extend Aquadex use from 20 kg to patients weighing 5 kg and above, widening its addressable market. Pediatrics is becoming the growth engine. Management has said pediatric cases now represent roughly 50% of U.S. revenue across about 47 centers, including several top-ranked children's hospitals.
Nuwellis (NUWE) fell roughly 12% over the trailing 30 days on a split-adjusted basis, from about $6.48 on September 30 to $5.68 at the October 30 close. The move was punctuated by a 1-for-9 reverse stock split that took effect in late October and by extreme, single-day volume spikes in the week that followed.
The central target of $3.25 is the average of the verified analyst price targets that sit above the current share price, since the overall mean of all valid targets (roughly $3.17) is less than 10% above the latest price. Shares of Quanterix Corporation (QTRX) last traded near $2.90, so reaching $3.25 implies an upside of roughly 12%.
The central target of $37 reflects the average of the two current analyst price targets that sit above the latest market price, not a full consensus figure. Across eight verified analyst targets, the range is $27 to $38, with an overall mean of roughly $30.75 — essentially at or below the recent share price.
Commercialization inflection point: With the LIBERTY Endovascular Robotic System now FDA-cleared and past its Limited Market Release phase, the company's 2026 focus shifts to scaling the Full Market Release and converting early hospital adopters into recurring utilization. International catalysts stack up: CE Mark (European conformity certification) approval is targeted for late Q4 2026 or early Q1 2027, alongside Israel clearance and expansion into Asia and the Middle East, positioning MBOT for a broader addressable market.
Regulatory inflection point ahead: The most consequential near-term catalyst is the U.S. Food and Drug Administration (FDA) decision on the second-generation LungFit PH system, which is seeking expanded labeling for use during patient transport by air and ground. Market expansion tied to approval: If cleared, management estimates the U.S. addressable market could expand roughly fourfold to about $400 million, with a worldwide opportunity exceeding $1 billion.
The central price target of $5.40 is the arithmetic mean of four verified analyst price targets collected from individual firm reports, not a single headline estimate. At roughly $1.09, the shares would need to gain about 395% to reach $5.40 — a very large move by any standard.
The central price target of $20 is the arithmetic mean of the two current analyst price targets — $10 and $30 — tracked by S&P Global for Beyond Air, Inc. , and it implies roughly a 793% move from the most recent close of $2.24. Coverage is exceptionally thin — roughly two to three analysts — and the target range is unusually wide, from about $10 to roughly $31.50, reflecting deep disagreement about the company's commercialization timeline.
Microbot Medical (MBOT) develops the LIBERTY Endovascular Robotic Surgical System, a single-use, FDA-cleared robotic platform for peripheral vascular interventions, and is in the earliest stage of commercialization. The stock traded near $1.09 as of late October 2026, roughly 9% below its late-September close, reflecting a consolidating pullback within a highly volatile trading year.
Beyond Air (XAIR) shares fell roughly 18% over the last 30 days, sliding from about $2.76 to approximately $2.26 per share. The decline extended a broader multi-month downtrend, with the stock down more than 50% over the past quarter.
Growth inflection: Medtronic exited fiscal 2026 (the year ended April 2026) with its strongest revenue growth in a decade, and management's fiscal 2027 guidance calls for continued mid-to-high single-digit organic expansion. Four "generational" catalysts: The pulsed field ablation (PFA) platform for atrial fibrillation, the Symplicity Spyral renal denervation system, the Altaviva neuromodulation device, and the Hugo surgical robot are each positioned to scale toward $1 billion-plus revenue opportunities.
Previous
18 of 31
Next